The stock of Alcobra Ltd (NASDAQ:ADHD) is a huge mover today! The stock closed at $1.92 during the last session. It is up 47.83% since March 29, 2016 and is downtrending. It has underperformed by 51.30% the S&P500.
The move comes after 9 months positive chart setup for the $47.04 million company. It was reported on Oct, 31 by Barchart.com. We have $3.11 PT which if reached, will make NASDAQ:ADHD worth $29.16 million more.
Alcobra Ltd (NASDAQ:ADHD) Ratings Coverage
Out of 6 analysts covering Alcobra (NASDAQ:ADHD), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. Alcobra has been the topic of 12 analyst reports since August 9, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Tuesday, June 7 by Cantor Fitzgerald. Zacks upgraded Alcobra Ltd (NASDAQ:ADHD) on Monday, August 17 to “Hold” rating. The firm has “Underweight” rating given on Friday, October 28 by Barclays Capital. The stock has “Outperform” rating given by Oppenheimer on Monday, January 25. On Thursday, February 18 the stock rating was initiated by Jefferies with “Buy”. As per Monday, August 1, the company rating was initiated by Barclays Capital. TH Capital maintained Alcobra Ltd (NASDAQ:ADHD) rating on Friday, August 14. TH Capital has “Buy” rating and $16 price target. The stock has “Buy” rating given by Roth Capital on Tuesday, June 21. As per Sunday, August 9, the company rating was maintained by WBB Securities. Roth Capital initiated Alcobra Ltd (NASDAQ:ADHD) on Thursday, February 4 with “Buy” rating.
According to Zacks Investment Research, “Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel.”
More recent Alcobra Ltd (NASDAQ:ADHD) news were published by: Globenewswire.com which released: “Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study” on September 29, 2016. Also Quotes.Wsj.com published the news titled: “Alcobra Ltd. ADHD (US: Nasdaq)” on May 18, 2013. Streetinsider.com‘s news article titled: “Alcobra Ltd. (ADHD) Receives Written Full Clinical Hold from FDA on MDX Phase 3” with publication date: October 07, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.